![colored background colored background](/content/dam/bostonscientific/pi/portfolio-group/InterventionalOncology/therasphere/proven-results/legacy-study-TheraSphere-Promo.png)
The TARGET Study
A global real-world retrospective study that confirms TheraSphere for HCC as safe and effective, demonstrating predictable clinical outcomes across a broad patient population in 8 countries.
Lam, M., Garin, E., Maccauro, M. et al. A global evaluation of advanced dosimetry in transarterial radioembolisation of hepatocellular carcinoma with Yttrium-90: the TARGET study. Eur J Nucl Med Mol Imaging (2022). https://doi.org/10.1007/s00259-022-05774-0
Study Objective
Establish the relationships between:
- Normal tissue adsorbed dose (NTAD) and occurrence of grade 3 or higher hyperbilirubinemia
- Tumour absorbed dose (TAD) and Objective Response Rate (ORR)
- TAD and Overall Survival (OS)
Study Design
Key Patient Characteristics
- Mainly Intermediate and Advanced HCC: 33% BCLC B and 55% BCLC C
- 7cm median target lesion
- 33% PVT
Dosimetry Approach
- Investigator review of patient chart and dosimetry calculation
- Retrospective dosimetry evaluation with multi-compartment approach using Simplicit90Y™ personalised dosimetry software to determine TAD and NTAD
Results
Tumour Absorbed Dose Was Predictive of Response1,2
Tumour Absorbed Dose Was Predictive of Overall Survival
Low Rate of ≥ Grade 3 Hyperbilirubinemia Confirms Safety of TARGET Study
![The TARGET Study Patient Characteristics 1.](https://www.bostonscientific.com/en-EU/medical-specialties/interventional-radiology/interventional-oncology/latest-evidence/target-study/_jcr_content/fullBleedTileContent-par/fullbleedtile_copy_c_869221234/maincontentFullBleed-par/image_678170221_copy.img.patient-characteristics-1.jpg)
![The TARGET Study Patient Characteristics 2.](https://www.bostonscientific.com/en-EU/medical-specialties/interventional-radiology/interventional-oncology/latest-evidence/target-study/_jcr_content/fullBleedTileContent-par/fullbleedtile_copy_c_869221234/maincontentFullBleed-par/image_816277952_copy.img.patient-characteristics-2.jpg)
![colored background colored background](/content/dam/bostonscientific/pi/portfolio-group/InterventionalOncology/therasphere/proven-results/legacy-study-TheraSphere-Promo.png)
Study Takeaways
|
|
|
![THERASPHRER™ THERASPHRER™](/content/dam/bostonscientific/pi/portfolio-group/InterventionalOncology/eu/featured-block-2.jpg)
Perform SIRT with TheraSphere™
![SIMPLICIT<sup>90</sup>Y™ SIMPLICIT<sup>90</sup>Y™](/content/dam/bostonscientific/pi/portfolio-group/InterventionalOncology/eu/featured-block-3.jpg)
SIMPLICIT90Y™
Embrace Y90
SIRT Personalised Dosimetry
SIRT Personalised Dosimetry
![Physician Education Physician Education](/content/dam/bostonscientific/pi/portfolio-group/InterventionalOncology/eu/light-blue-bg-image.jpg)
Virtual Events
View our latest virtual symposia and webinars on interventional oncology topics.
![Stay up to date Stay up to date](/content/dam/bostonscientific/pi/portfolio-group/InterventionalOncology/eu/orange-bg-image.jpg)
Stay up to date
Receive emails about the latest interventional oncology news, innovations and events.